OverviewSuggest Edit

Scholar Rock® is discovering and developing a new class of biologic therapies to selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation, resulting in therapeutic effects specifically at the source of disease. Our proprietary technology has a unique capability for highly selective targeting of growth factors which play a fundamental role in regulating cell growth and differentiation. Modulating supracellular activation is relevant to a wide range of diseases including fibrosis, diseases of musculoskeletal systems, autoimmune diseases, and cancer. Scholar Rock has a highly experienced management team with leaders who have helped to build successful biotech companies. The company was founded by distinguished scientists, Dr. Timothy Springer and Dr. Leonard Zon, whose key discoveries in growth factor biology are enabling the company’s therapeutic approach. ... Show more
HQCambridge, US
Employee Ratings0

Latest Updates

Employees (est.) (Feb 2019)70(+3%)

Key People/Management at Scholar Rock

Nagesh K. Mahanthappa

Nagesh K. Mahanthappa


Scholar Rock Office Locations

Scholar Rock has an office in Cambridge
Cambridge, US (HQ)
620 Memorial Dr
Show all (1)
Report incorrect company information

Scholar Rock Financials and Metrics

Summary Metrics

Founding Date


Scholar Rock total Funding

$103 m

Scholar Rock latest funding size

$47 m

Time since last funding

a year ago

Scholar Rock investors

Scholar Rock's latest funding round in January 2018 was reported to be $47 m. In total, Scholar Rock has raised $103 m
View all funding rounds
Report incorrect company information

Scholar Rock News and Updates

Scholar Rock to Present Preclinical Data Highlighting the Role of TGFβ1 Inhibition in Overcoming Checkpoint Resistance at the SITC Annual Meeting

CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that new preclinical data from its TGFβ1 cancer immunoth…

Scholar Rock stock tumbles 11% as Pfizer discontinues similar medication

Scholar Rock Holding Corp. shares dropped 11% in active Thursday trade after Pfizer Inc. announced it plans to stop two ongoing clinical trials for a similar rare-disease drug. The Pfizer drug in question, domagrozumab, was designed to block a protein that is involved in muscle growth called myost…

Biotech company Scholar Rock lands $47 mln Series C

Scholar Rock, a biotechnology company, has secured $47 million in Series C financing. Invus led the round with participation from other investors that included Redmile Group, Polaris Partners, Timothy Springer, ARCH Venture Partners, EcoR1 Capital, The Kraft Group, Fidelity Management and Research C…
Report incorrect company information

Scholar Rock Blogs

“Act 2” for Checkpoint Blockade Therapies in Cancer: Defeating Primary Resistance

Without a doubt, recent advances in immunotherapy have transformed the treatment of patients with cancer. Many patients with previously intractable cancers are now stabilized or have even had their cancer rendered undetectable. The astounding results seen with checkpoint blockade therapies (CBTs), p…

Scholar Rock Company Life and Culture

Report incorrect company information

Scholar Rock Frequently Asked Questions

  • When was Scholar Rock founded?

    Scholar Rock was founded in 2012.

  • Who are Scholar Rock key executives?

    Scholar Rock's key executives are Nagesh K. Mahanthappa.

  • How many employees does Scholar Rock have?

    Scholar Rock has 70 employees.

  • Who are Scholar Rock competitors?

    Competitors of Scholar Rock include Biogen, MyoKardia and Athersys.

  • Where is Scholar Rock headquarters?

    Scholar Rock headquarters is located at 620 Memorial Dr, Cambridge.

  • Where are Scholar Rock offices?

    Scholar Rock has an office in Cambridge.

  • How many offices does Scholar Rock have?

    Scholar Rock has 1 office.